EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

RBBP6 and cancer: from molecular mechanisms to clinical implications

Philemon N Ubanako, Ekene E Nweke, Zanele Nsingwane, Bernice Monchusi, Clement Penny

Frontiers in Oncology · 19.05.2026 · 16

DOI: 10.3389/fonc.2026.1841906 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 19.05.2026. Verfasst von Philemon N Ubanako und 4 weiteren Autor:innen. Beteiligte Einrichtung: Molecular and Cellular Oncology Research Group, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johanne…. Die Arbeit nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Retinoblastoma binding protein 6 (RBBP6) is a 200 kDa E3 ubiquitin ligase that performs several biological functions and plays a role in tumorigenesis. RBBP6 is overexpressed in several types of tumors, including lung, colorectal, breast, cervical, hepatocellular, and esophageal cancers, suggesting its association with malignant progression. Moreover, this increased expression has been associated with clinicopathological parameters in lung, colorectal, cervical, and ovarian cancers. This review captures the molecular functions of RBBP6 and the mechanisms by which aberrant RBBP6 expression and function influence cancer development and therapeutic response. These mechanisms include its ability to interact with E3 ligase substrates, Jun N-terminal kinase (JNK), noncoding RNAs, and DNA damage-associated proteins to promote cell proliferation, stemness, cell cycle progression, and metastasis. We also evaluated the prognostic and predictive significance of RBBP6 as a potential cancer biomarker and its suitability as a molecular target in cancer. This is the first review that comprehensively explores the multifaceted molecular mechanisms by which RBBP6 influences cancer progression in several cancer types.

Schlagwörter

Stichwörter der Autor:innen

RBBP6biomarkercancercarcinogenesisgene regulationmolecular mechanismsposttranslational modificationsubiquitin ligase

Autor:innen und Institutionen

  • Molecular and Cellular Oncology Research Group, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Department of Surgery, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Department of Life and Consumer Sciences, University of South Africa, Johannesburg, South Africa.
  • Wits Diagnostic and Innovation Hub, Wits Health Consortium, University of the Witwatersrand, Johannesburg, South Africa.
  • Department of Biosciences, Council for Scientific and Industrial Research (CSIR), Pretoria, South Africa.

Zitieren

APA

Ubanako, P. N., Nweke, E. E., Nsingwane, Z., Monchusi, B., & Penny, C. (2026). RBBP6 and cancer: from molecular mechanisms to clinical implications. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1841906

Vancouver

Ubanako PN, Nweke EE, Nsingwane Z, Monchusi B, Penny C. RBBP6 and cancer: from molecular mechanisms to clinical implications. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1841906

BibTeX
@article{Ubanako2026,
  author = {Ubanako, Philemon N and Nweke, Ekene E and Nsingwane, Zanele and Monchusi, Bernice and Penny, Clement},
  title = {RBBP6 and cancer: from molecular mechanisms to clinical implications},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1841906}
}
Kostenlos starten →